- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03708744
A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
A Randomized Open-label 4-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 at Two Different Application Locations for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time in Healthy Volunteers
This is a single-center, open-label, randomized, four-way crossover study. Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for pharmacokinetic analysis.
Dosing will occur approximately 48 hours apart, until completion of dosing in randomized order per the treatment sequence tables. Plasma samples from the dosing days will be sent to the analytical laboratory for analysis and tolerability for each of the dose levels will be summarized.
After completion of the four dosing days, subjects will be assessed one final time and dismissed from the study.
Study Overview
Status
Conditions
Detailed Description
This is a single-center, open-label, randomized, four-way crossover study to compare the pharmacokinetics, safety and tolerability of:
M207 3.8 mg administered to the upper arm to M207 3.8 mg administered to the thigh, particularly with respect to skin irritation (erythema, edema, bruising, bleeding):
M207 3.8 mg worn for 30 minutes on the upper arm to M207 3.8 mg worn for 1 hour on the upper arm; and M207 3.8 mg to intranasal zolmitriptan 2.5 mg.
Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for pharmacokinetic analysis.
M207 application sites will be observed for erythema, edema, bruising, and bleeding at various timepoints throughout the study.
Dosing will occur approximately 48 hours apart, until completion of dosing in randomized order per the treatment sequence tables. Plasma samples from the dosing days will be sent to the analytical laboratory for analysis and tolerability for each of the dose levels will be summarized.
After completion of the four dosing days, subjects will be assessed one final time and dismissed from the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Neptune, New Jersey, United States, 07753
- Hill Top Research, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women or men 18 to 50 years of age.
- Good general health with no clinically significant abnormalities as determined by medical history, physical examination, complete blood count (CBC), blood chemistry, urinalysis, and ECG.
- Negative urine drug and alcohol screens and negative serum pregnancy tests (for female subjects) at screening.
- Consent of female subjects to use a medically effective method of contraception throughout the entire study period and for 30 days after the subject completes the study. Medically effective methods of contraception that may be used by the subject include abstinence, use of diaphragm and spermicide, intrauterine device (IUD), condom and vaginal spermicide, hormonal contraceptives (subjects must be stable on hormonal contraceptives for at least the prior 3 months), surgical sterilization, and post-menopausal (≥ 2 years of amenorrhea).
- Ability to read, understand, and provide written informed consent that they understand the purpose of the study and procedures required for the study before enrolling in the study, and willingness to comply with all study procedures and restrictions.
Exclusion Criteria:
- Evidence of significant history of hepatic, reproductive, gastrointestinal, renal, bleeding, or hematological disorders including coagulation, pulmonary, neurological, respiratory, endocrine, or cardiovascular system abnormalities (especially hypertension, peripheral vascular disease, coronary artery disease, transient ischemic attacks, or cardiac rhythm abnormalities), psychiatric disorders, acute infection, or other conditions that would interfere with study participation or with the absorption, distribution, metabolism, or excretion of drugs.
- Presence of two or more risk factors for cardiovascular disease (family history of premature heart disease, hyperlipidemia, or hypertension)
Any contraindication to zolmitriptan administration including:
- History of coronary artery disease or coronary vasospasm
- Symptomatic Wolf-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
- History of stroke, transient ischemic attack, or hemiplegic or basilar migraine
- Peripheral Vascular Disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Any history of hepatic impairment
- History of contact dermatitis or known dermatological disorders that would interfere with the study procedures or assessments
- Planned participation in activities which cause inflammation, irritation, sunburn, lesions, or tattoos at the intended application sites from 2 weeks prior to screening through their last day of study participation
- Use of warfarin within 1 month prior to the first dose or heparin within 1 week prior to study drug administration
Use of prescription and over the counter medications other than the following:
- Hormone Replacement Therapy (HRT)
- Birth control pills, patches, injections, or implants (all hormonal contraceptives) are allowed provided the dose has been stable for at least one month prior to screening and may be continued throughout the study
- Antihistamines
- Intermittently used NSAIDS
- Acetaminophen if medically necessary (not more than 2 g/day)
- Exceptions may be allowed on a case by case basis
- Subjects who have a known allergy or sensitivity to zolmitriptan or its derivatives or formulations
- Known allergy or sensitivity to tapes, adhesives, or zolmitriptan
- Regular or recent intake of prescription drugs, particularly drugs with an influence on blood pressure.
- Use of any other investigational compound within one month of planned study drug dosing
- On-going drug or alcohol abuse, or history of either deemed to be clinically significant by the investigator
- Systolic BP (measured after remaining sitting for 5 minutes) greater than 140 mmHg and diastolic BP greater than 90 mmHg at screening
- History of nasal pathology (e.g., polyps) or abnormal nasal exam
- Body Mass Index (BMI) greater than 35 kg/m2
- If, in the opinion of the investigator, the subject is not suitable for the study
- Any positive urine drug screen result or alcohol breath test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
|
A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Other Names:
B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Other Names:
C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Other Names:
D: 2.5 mg/0.1 mL intranasal zolmitriptan
Other Names:
|
Experimental: Treatment B
Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
|
A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Other Names:
B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Other Names:
C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Other Names:
D: 2.5 mg/0.1 mL intranasal zolmitriptan
Other Names:
|
Experimental: Treatment C
Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
|
A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Other Names:
B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Other Names:
C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Other Names:
D: 2.5 mg/0.1 mL intranasal zolmitriptan
Other Names:
|
Active Comparator: Treatment D
Treatment D: Intranasal zolmitriptan 2.5 mg
|
A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Other Names:
B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Other Names:
C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Other Names:
D: 2.5 mg/0.1 mL intranasal zolmitriptan
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose
|
maximum observed plasma concentration
|
pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 24 hours
|
number of subjects that experienced at least one adverse event
|
24 hours
|
t(1/2)
Time Frame: pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose
|
apparent half-life
|
pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Don Kellerman, Pharm.D., Zosano Pharma Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-2018-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on A: M207 3.8mg, 30 min, upper arm
-
Centre Hospitalier de NiortRecruitingDifficult or Failed Intubation | Reaction AnxietyFrance
-
University Hospitals Coventry and Warwickshire...Immunic AG; University of Warwick; MODEPHARMACompleted
-
University of LeicesterUniversity Hospitals, Leicester; Freemasons' Medical Research FundingCompletedPost Myocardial InfarctionUnited Kingdom
-
AcelRx Pharmaceuticals, Inc.Completed
-
University of Nevada, Las VegasCompletedParkinson's DiseaseUnited States
-
Beth ChristianGenentech, Inc.; CelgeneActive, not recruitingRecurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditionsUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic SyndromeUnited States
-
Washington University School of MedicineTerminatedMultiple MyelomaUnited States
-
Duke UniversityNational Institute of Mental Health (NIMH)Completed